Sabin Begins Marburg Vaccine Trial in U.S.

Published on May 28, 2025

Sabin has launched a Phase 2 Marburg virus vaccine trial in the U.S., building on studies in Kenya and Uganda. The trial will assess safety and immune response in 200 adults across four U.S. sites. Read more about this critical step toward protecting against future outbreaks.

Access the Article!
 
 
 
Other news

Sabin Gold Medal and Rising Star Award

May 28, 2025
The Sabin Vaccine Institute has honored Dr. Kate O’Brien with the 2025 Gold Medal for her groundbreaking leadership in global immunization and Boost Member Dr. Livancliff Mbianke of Cameroon with the Rising Star Award for expanding vaccine access in fragile settings. We encourage you to read the story and watch the live ceremony to learn more about these inspiring champions and their impactful wor

Q&A: Behind the Marburg Virus Outbreak in Rwanda

May 28, 2025
In response to Rwanda’s first Marburg virus outbreak in September 2024, Sabin quickly delivered 2,700 vaccine doses to support a clinical trial for frontline workers. The outbreak was contained by December, highlighting the impact of rapid response and collaboration. To learn more, click the link below!